Ultragenyx Pharmaceutical Inc
For the period ended Dec 31, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
RARE$16.41+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents(1) | $173,729 | $213,584 |
| Marketable debt securities | 436,296 | 363,625 |
| Accounts receivable, net | 121,801 | 73,390 |
| Inventory | 45,007 | 33,969 |
| Prepaid expenses and other assets | 40,290 | 47,616 |
| Total current assets | 817,123 | 732,184 |
| Property, plant, and equipment, net | 265,929 | 290,566 |
| Marketable debt securities | 135,004 | 199,901 |
| Intangible assets, net | 178,314 | 166,271 |
| Goodwill | 44,406 | 44,406 |
| Other assets | 62,680 | 57,685 |
| Total assets | $1,503,456 | $1,491,013 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $38,756 | $42,114 |
| Accrued liabilities | 240,973 | 196,486 |
| Lease liabilities | 10,297 | 12,595 |
| Liabilities for sales of future royalties | 49,847 | 29,242 |
| Other liabilities | 4,280 | — |
| Total current liabilities | 344,153 | 280,437 |
| Lease liabilities | 30,042 | 30,574 |
| Deferred tax liabilities | 30,058 | 30,058 |
| Liabilities for sales of future royalties | 819,824 | 862,325 |
| Other liabilities | 17,082 | 12,205 |
| Total liabilities | 1,241,159 | 1,215,599 |
| Commitments and contingencies (Note 16) | ||
| Noncontrolling interest | 7,000 | — |
| Stockholders’ equity: | ||
| Preferred stock, par value of $0.001 per share—25,000,000 shares authorized; nil outstanding in 2024 and in 2023 | — | — |
| Common stock, par value of $0.001 per share—250,000,000 shares authorized; outstanding—92,484,330 in 2024 and 82,315,590 in 2023 | 92 | 82 |
| Treasury stock, at cost, 69,757 in 2024 and 9,559 in 2023 | (3,593) | (432) |
| Deferred compensation obligation | 3,593 | 432 |
| Additional paid-in capital | 4,212,692 | 3,662,346 |
| Accumulated other comprehensive (loss) income | (643) | 647 |
| Accumulated deficit | (3,956,844) | (3,387,661) |
| Total stockholders’ equity | 255,297 | 275,414 |
| Total liabilities, noncontrolling interest and stockholders’ equity | $1,503,456 | $1,491,013 |
(1)
The Company's Consolidated Balance Sheet as of December 31, 2024 includes $13.5 million in cash and cash equivalents that can be used only to settle obligations of the consolidated variable interest entity. See "Note 7. Investment in Amlogenyx Inc."
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.